As a principle we (Professor Giovannoni and his team) will attempt to declare all relevant conflicts of interest in relation to our postings. We realise the success of this blog depends on us being independent, or at least being transparent, and declaring our conflicts of interest in relation to specific postings.  

However, we have many conflicts of interest and therefore read this information with this in,and an open,mind.

Professor Giovannoni and his group have received research grant support from Bayer-Schering Healthcare, Biogen-Idec, Genzyme, GW Pharma, Ironwood, Merck, Merck-Serono, Merz, Novartis, Teva and Sanofi-Aventis. He has received personal compensation for participating on advisory boards, trial steering committees and trial data and safety monitoring boards from: AbbVie, Atara Bio, Bayer-Schering Healthcare, Biogen, Canbex, Eisai, Elan, Fiveprime, Genzyme-Sanofi, Genentech, GSK, GW Pharma, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. 

MouseDoctor is founder/shareholder of a University Spinout Company, Canbex, aiming to develop new anti-symptomatic drugs for MS. He has provided ad-hoc consultancies and/or been the recipient of research grants/contracts from some of the companies mentioned above. He supports the concept of off label DMT use. He recieved personal compensation from Sanofi Genzyme and Japanese Tobacco, Canbex Therapeutics

MouseDoctor2 as an inventor is a shareholder in the University Spinout Company and has undertaken contract research testing for some of the companies mentioned above. 

We have received grant support from companies and Aims2cure; The National Multiple Sclerosis Society, The Multiple Sclerosis Society, The Wellcome Trust; The Medical Research Council; Innovate UK; Fastforward and others, for which we are very grateful.
Klaus Schmierer (DrK) is a principal investigator of trials sponsored by Novartis, Roche and Teva.  He is also involved in trials sponsored by Biogen, Genzyme, BIAL, has received speaking honoraria from, and/or served in an advisory role for, Biogen, Novartis, Teva, Merck, Merck Inc., and support to attend meetings from Genzyme and Novartis. DrK and his group have received research grant support from Novartis, the Wellcome Trust, the National MS Society (US), the MS Society of Great Britain & Northern Ireland, the Royal College of Radiologists, and Barts Charity. 

NeuroDoc Gnanapavan has served in an advisory role for Novartis and received travel support from Teva and Novartis. She has received research grant support from the National MS Society (US).

Updated, 1st March 2018